Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Bachert (Ghent, Belgium), J. Mullol (Barcelona, Spain), N. Daizadeh (Cambridge, United States of America), K. Wolfe (Bridgewater, United States of America), B. Ortiz (Tarrytown, United States of America), R. Johnson (Bridgewater, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France), N. Amin (Tarrytown, United States of America), S. Harel (Tarrytown, United States of America), A. Jagerschmidt (Chilly-Mazarin, France). Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial. 1117

Member's Comments

No comment yet.

Related content which might interest you: Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 The prevelance of chronic nasal symptoms in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 264s Year: 2002 Chronic paranasal sinusitis exacerbates allergic inflammation in patients with asthma and contributes to refractoriness to treatment Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Impact of chronic rhinosinusitis on clinical presentation in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 238s Year: 2006 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema Source: Eur Respir J 2001; 17: 596-603 Year: 2001 Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Neutrophilic inflammation in nasal lavage (NL) and induced sputum (IS) from patients with chronic sinusitis or chronic sinusitis and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003